Annual Operating Profit
-$10.19 M
+$9.07 M+47.09%
April 30, 2024
Summary
- As of February 8, 2025, IPA annual operating income is -$10.19 million, with the most recent change of +$9.07 million (+47.09%) on April 30, 2024.
- During the last 3 years, IPA annual operating profit has fallen by -$7.00 million (-219.34%).
- IPA annual operating profit is now -188616.67% below its all-time high of -$5400.00, reached on December 31, 2015.
Performance
IPA Operating Profit Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Operating Profit
-$2.06 M
+$1.31 M+38.88%
October 31, 2024
Summary
- As of February 8, 2025, IPA quarterly operating income is -$2.06 million, with the most recent change of +$1.31 million (+38.88%) on October 31, 2024.
- Over the past year, IPA quarterly operating profit has increased by +$1.31 million (+38.88%).
- IPA quarterly operating profit is now -2396.55% below its all-time high of $89.90 thousand, reached on December 1, 2006.
Performance
IPA Quarterly Operating Profit Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM Operating Profit
-$10.51 M
$300.000.00%
October 31, 2024
Summary
- As of February 8, 2025, IPA TTM operating income is -$10.51 million, with the most recent change of +$300.00 (0.00%) on October 31, 2024.
- Over the past year, IPA TTM operating profit has stayed the same.
- IPA TTM operating profit is now -57508.20% below its all-time high of $18.30 thousand, reached on September 30, 2015.
Performance
IPA TTM Operating Profit Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Operating Profit Formula
Operating Profit = Gross Profit − Operating Expenses
IPA Operating Profit Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +47.1% | +38.9% | 0.0% |
| 3 y3 years | -219.3% | +38.9% | 0.0% |
| 5 y5 years | -115.7% | +38.9% | 0.0% |
IPA Operating Profit Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -219.3% | +47.1% | at high | +72.9% | -6.2% | +48.0% |
| 5 y | 5-year | -255.6% | +47.1% | -2936.2% | +72.9% | -571.0% | +48.0% |
| alltime | all time | <-9999.0% | +47.1% | -2396.6% | +72.9% | <-9999.0% | +48.0% |
ImmunoPrecise Antibodies Operating Profit History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Oct 2024 | - | -$2.06 M(-38.9%) | -$10.51 M(-0.0%) |
| Jul 2024 | - | -$3.38 M(+30.4%) | -$10.51 M(+5.6%) |
| Apr 2024 | -$10.19 M(-47.1%) | -$2.59 M(+4.8%) | -$9.95 M(+0.5%) |
| Jan 2024 | - | -$2.47 M(+19.8%) | -$9.90 M(-8.4%) |
| Oct 2023 | - | -$2.06 M(-26.8%) | -$10.80 M(-26.0%) |
| Jul 2023 | - | -$2.82 M(+11.1%) | -$14.60 M(-24.7%) |
| Apr 2023 | -$19.26 M(+44.9%) | -$2.54 M(-24.9%) | -$19.39 M(-4.1%) |
| Jan 2023 | - | -$3.38 M(-42.4%) | -$20.22 M(+0.0%) |
| Oct 2022 | - | -$5.87 M(-22.9%) | -$20.21 M(+11.9%) |
| Jul 2022 | - | -$7.61 M(+126.0%) | -$18.06 M(+36.9%) |
| Apr 2022 | -$13.29 M(+316.4%) | -$3.37 M(-0.1%) | -$13.20 M(+11.9%) |
| Jan 2022 | - | -$3.37 M(-9.2%) | -$11.79 M(+28.7%) |
| Oct 2021 | - | -$3.71 M(+35.2%) | -$9.16 M(+54.0%) |
| Jul 2021 | - | -$2.75 M(+40.1%) | -$5.95 M(+82.0%) |
| Apr 2021 | -$3.19 M(+11.3%) | -$1.96 M(+164.5%) | -$3.27 M(+51.5%) |
| Jan 2021 | - | -$741.20 K(+48.7%) | -$2.16 M(+37.8%) |
| Oct 2020 | - | -$498.30 K(+632.8%) | -$1.57 M(-13.8%) |
| Jul 2020 | - | -$68.00 K(-92.0%) | -$1.82 M(-36.4%) |
| Apr 2020 | -$2.87 M(-39.3%) | -$849.20 K(+465.8%) | -$2.85 M(-37.6%) |
| Jan 2020 | - | -$150.10 K(-80.0%) | -$4.57 M(-9.4%) |
| Oct 2019 | - | -$749.10 K(-32.3%) | -$5.05 M(-2.4%) |
| Jul 2019 | - | -$1.11 M(-56.9%) | -$5.17 M(+9.9%) |
| Apr 2019 | -$4.72 M(+26.6%) | -$2.57 M(+310.3%) | -$4.71 M(+29.6%) |
| Jan 2019 | - | -$625.80 K(-28.2%) | -$3.63 M(-5.9%) |
| Oct 2018 | - | -$871.80 K(+36.2%) | -$3.86 M(+3.5%) |
| Jul 2018 | - | -$640.00 K(-57.1%) | -$3.73 M(-0.2%) |
| Apr 2018 | -$3.73 M(+271.5%) | -$1.49 M(+74.9%) | -$3.73 M(+23.7%) |
| Jan 2018 | - | -$853.10 K(+15.2%) | -$3.02 M(+15.9%) |
| Oct 2017 | - | -$740.50 K(+14.5%) | -$2.60 M(+39.0%) |
| Jul 2017 | - | -$646.70 K(-16.7%) | -$1.87 M(+51.9%) |
| Apr 2017 | -$1.00 M(>+9900.0%) | -$776.00 K(+76.7%) | -$1.23 M(+169.8%) |
| Jan 2017 | - | -$439.20 K(+4082.9%) | -$456.90 K(+1327.8%) |
| Sep 2016 | - | -$10.50 K(+45.8%) | -$32.00 K(+35.0%) |
| Jun 2016 | - | -$7200.00(+132.3%) | -$23.70 K(+141.8%) |
| Mar 2016 | - | -$3100.00(-72.3%) | -$9800.00(+117.8%) |
| Dec 2015 | -$5400.00(-83.8%) | - | - |
| Dec 2015 | - | -$11.20 K(+409.1%) | -$4500.00(-124.6%) |
| Sep 2015 | - | -$2200.00(-132.8%) | $18.30 K(-385.9%) |
| Jun 2015 | - | $6700.00(+204.5%) | -$6400.00(-56.8%) |
| Mar 2015 | - | $2200.00(-81.0%) | -$14.80 K(-56.6%) |
| Dec 2014 | -$33.40 K(-61.6%) | - | - |
| Dec 2014 | - | $11.60 K(-143.1%) | -$34.10 K(-58.3%) |
| Sep 2014 | - | -$26.90 K(+1482.4%) | -$81.70 K(+8.2%) |
| Jun 2014 | - | -$1700.00(-90.1%) | -$75.50 K(-12.2%) |
| Mar 2014 | - | -$17.10 K(-52.5%) | -$86.00 K(-0.6%) |
| Dec 2013 | -$87.00 K(+7.1%) | - | - |
| Dec 2013 | - | -$36.00 K(+73.9%) | -$86.50 K(+1.4%) |
| Sep 2013 | - | -$20.70 K(+69.7%) | -$85.30 K(+2.8%) |
| Jun 2013 | - | -$12.20 K(-30.7%) | -$83.00 K(+7.5%) |
| Mar 2013 | - | -$17.60 K(-49.4%) | -$77.20 K(-5.2%) |
| Dec 2012 | -$81.20 K(-61.4%) | - | - |
| Dec 2012 | - | -$34.80 K(+89.1%) | -$81.40 K(-10.9%) |
| Sep 2012 | - | -$18.40 K(+187.5%) | -$91.40 K(-33.6%) |
| Jun 2012 | - | -$6400.00(-70.6%) | -$137.60 K(-29.1%) |
| Mar 2012 | - | -$21.80 K(-51.3%) | -$194.10 K(+12.3%) |
| Dec 2011 | -$210.10 K(-17.1%) | - | - |
| Dec 2011 | - | -$44.80 K(-30.7%) | -$172.80 K(-23.2%) |
| Sep 2011 | - | -$64.60 K(+2.7%) | -$225.00 K(+7.6%) |
| Jun 2011 | - | -$62.90 K(>+9900.0%) | -$209.10 K(+42.3%) |
| Mar 2011 | - | -$500.00(-99.5%) | -$146.90 K(-28.8%) |
| Dec 2010 | -$253.50 K(+7.2%) | - | - |
| Dec 2010 | - | -$97.00 K(+99.2%) | -$206.30 K(-0.4%) |
| Sep 2010 | - | -$48.70 K(+6857.1%) | -$207.10 K(-0.3%) |
| Jun 2010 | - | -$700.00(-98.8%) | -$207.80 K(-15.7%) |
| Mar 2010 | - | -$59.90 K | -$246.60 K |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2009 | -$236.50 K(-36.2%) | - | - |
| Dec 2009 | - | -$97.80 K(+98.0%) | -$239.00 K(-44.3%) |
| Sep 2009 | - | -$49.40 K(+25.1%) | -$428.70 K(+37.8%) |
| Jun 2009 | - | -$39.50 K(-24.5%) | -$311.10 K(-9.1%) |
| Mar 2009 | - | -$52.30 K(-81.8%) | -$342.20 K(-2.7%) |
| Dec 2008 | -$370.70 K(-35.6%) | - | - |
| Dec 2008 | - | -$287.50 K(-521.6%) | -$351.70 K(-36.2%) |
| Sep 2008 | - | $68.20 K(-196.6%) | -$551.50 K(-14.1%) |
| Jun 2008 | - | -$70.60 K(+14.2%) | -$642.20 K(+2.3%) |
| Mar 2008 | - | -$61.80 K(-87.3%) | -$627.70 K(+2.1%) |
| Dec 2007 | -$575.80 K(+175.2%) | - | - |
| Dec 2007 | - | -$487.30 K(+2065.8%) | -$614.70 K(+1539.2%) |
| Sep 2007 | - | -$22.50 K(-59.9%) | -$37.50 K(-24.7%) |
| Jun 2007 | - | -$56.10 K(+15.0%) | -$49.80 K(-75.7%) |
| Mar 2007 | - | -$48.80 K(-154.3%) | -$205.20 K(-0.9%) |
| Dec 2006 | -$209.20 K(+23.3%) | - | - |
| Dec 2006 | - | $89.90 K(-358.3%) | -$207.10 K(-41.6%) |
| Sep 2006 | - | -$34.80 K(-83.5%) | -$354.80 K(+5.7%) |
| Jun 2006 | - | -$211.50 K(+317.2%) | -$335.80 K(+109.0%) |
| Mar 2006 | - | -$50.70 K(-12.3%) | -$160.70 K(-42.1%) |
| Dec 2005 | -$169.70 K(+10.1%) | - | - |
| Dec 2005 | - | -$57.80 K(+265.8%) | -$277.70 K(-29.9%) |
| Sep 2005 | - | -$15.80 K(-56.6%) | -$396.10 K(+6.1%) |
| Jun 2005 | - | -$36.40 K(-78.3%) | -$373.20 K(+1.9%) |
| Mar 2005 | - | -$167.70 K(-4.8%) | -$366.10 K(+51.6%) |
| Dec 2004 | -$154.10 K(-30.2%) | - | - |
| Dec 2004 | - | -$176.20 K(-2581.7%) | -$241.50 K(+14.1%) |
| Sep 2004 | - | $7100.00(-124.2%) | -$211.60 K(-11.7%) |
| Jun 2004 | - | -$29.30 K(-32.0%) | -$239.60 K(-2.2%) |
| Mar 2004 | - | -$43.10 K(-70.5%) | -$245.00 K(+7.6%) |
| Dec 2003 | -$220.80 K(+119.7%) | - | - |
| Dec 2003 | - | -$146.30 K(+600.0%) | -$227.60 K(+122.3%) |
| Sep 2003 | - | -$20.90 K(-39.8%) | -$102.40 K(+0.3%) |
| Jun 2003 | - | -$34.70 K(+35.0%) | -$102.10 K(+0.6%) |
| Mar 2003 | - | -$25.70 K(+21.8%) | -$101.50 K(+0.9%) |
| Dec 2002 | -$100.50 K(-19.8%) | - | - |
| Dec 2002 | - | -$21.10 K(+2.4%) | -$100.60 K(+28.0%) |
| Sep 2002 | - | -$20.60 K(-39.6%) | -$78.60 K(-29.8%) |
| Jun 2002 | - | -$34.10 K(+37.5%) | -$112.00 K(-25.5%) |
| Mar 2002 | - | -$24.80 K(-2855.6%) | -$150.40 K(-0.7%) |
| Dec 2001 | -$125.30 K(+25.2%) | - | - |
| Dec 2001 | - | $900.00(-101.7%) | -$151.40 K(-15.7%) |
| Sep 2001 | - | -$54.00 K(-25.5%) | -$179.70 K(+21.3%) |
| Jun 2001 | - | -$72.50 K(+181.0%) | -$148.10 K(+46.1%) |
| Mar 2001 | - | -$25.80 K(-5.8%) | -$101.40 K(+1.5%) |
| Dec 2000 | -$100.10 K(-15.7%) | - | - |
| Dec 2000 | - | -$27.40 K(+22.3%) | -$99.90 K(+7.2%) |
| Sep 2000 | - | -$22.40 K(-13.2%) | -$93.20 K(-3.7%) |
| Jun 2000 | - | -$25.80 K(+6.2%) | -$96.80 K(-9.9%) |
| Mar 2000 | - | -$24.30 K(+17.4%) | -$107.40 K(-9.4%) |
| Dec 1999 | -$118.70 K(-1.8%) | - | - |
| Dec 1999 | - | -$20.70 K(-20.4%) | -$118.50 K(+7.6%) |
| Sep 1999 | - | -$26.00 K(-28.6%) | -$110.10 K(-5.2%) |
| Jun 1999 | - | -$36.40 K(+2.8%) | -$116.10 K(-5.5%) |
| Mar 1999 | - | -$35.40 K(+187.8%) | -$122.90 K(+0.8%) |
| Dec 1998 | -$120.90 K(-40.0%) | - | - |
| Dec 1998 | - | -$12.30 K(-61.6%) | -$121.90 K(-24.1%) |
| Sep 1998 | - | -$32.00 K(-25.9%) | -$160.70 K(-3.0%) |
| Jun 1998 | - | -$43.20 K(+25.6%) | -$165.70 K(-18.0%) |
| Mar 1998 | - | -$34.40 K(-32.7%) | -$202.00 K(+0.5%) |
| Dec 1997 | -$201.40 K(+23.9%) | - | - |
| Dec 1997 | - | -$51.10 K(+38.1%) | -$201.00 K(+34.1%) |
| Sep 1997 | - | -$37.00 K(-53.5%) | -$149.90 K(+32.8%) |
| Jun 1997 | - | -$79.50 K(+138.0%) | -$112.90 K(+238.0%) |
| Mar 1997 | - | -$33.40 K | -$33.40 K |
| Dec 1996 | -$162.50 K | - | - |
FAQ
- What is ImmunoPrecise Antibodies annual operating income?
- What is the all time high annual operating profit for ImmunoPrecise Antibodies?
- What is ImmunoPrecise Antibodies annual operating profit year-on-year change?
- What is ImmunoPrecise Antibodies quarterly operating income?
- What is the all time high quarterly operating profit for ImmunoPrecise Antibodies?
- What is ImmunoPrecise Antibodies quarterly operating profit year-on-year change?
- What is ImmunoPrecise Antibodies TTM operating income?
- What is the all time high TTM operating profit for ImmunoPrecise Antibodies?
- What is ImmunoPrecise Antibodies TTM operating profit year-on-year change?
What is ImmunoPrecise Antibodies annual operating income?
The current annual operating profit of IPA is -$10.19 M
What is the all time high annual operating profit for ImmunoPrecise Antibodies?
ImmunoPrecise Antibodies all-time high annual operating income is -$5400.00
What is ImmunoPrecise Antibodies annual operating profit year-on-year change?
Over the past year, IPA annual operating income has changed by +$9.07 M (+47.09%)
What is ImmunoPrecise Antibodies quarterly operating income?
The current quarterly operating profit of IPA is -$2.06 M
What is the all time high quarterly operating profit for ImmunoPrecise Antibodies?
ImmunoPrecise Antibodies all-time high quarterly operating income is $89.90 K
What is ImmunoPrecise Antibodies quarterly operating profit year-on-year change?
Over the past year, IPA quarterly operating income has changed by +$1.31 M (+38.88%)
What is ImmunoPrecise Antibodies TTM operating income?
The current TTM operating profit of IPA is -$10.51 M
What is the all time high TTM operating profit for ImmunoPrecise Antibodies?
ImmunoPrecise Antibodies all-time high TTM operating income is $18.30 K
What is ImmunoPrecise Antibodies TTM operating profit year-on-year change?
Over the past year, IPA TTM operating income has changed by +$300.00 (0.00%)